Concepedia

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Andrea Casadei‐Gardini, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa,

European Journal of Cancer · 2022 · 129 citations · 27 references

DOIFull text

Open access

Concepts

References

27

Sorafenib in Advanced Hepatocellular Carcinoma

Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al. · New England Journal of Medicine · 2008 · 13K citations · Full text

, , +12

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn, Shukui Qin, Masafumi Ikeda et al. · New England Journal of Medicine · 2020 · 7.2K citations · Full text

, , +12

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen et al. · The Lancet Oncology · 2008 · 5.8K citations

, , +11

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin et al. · The Lancet · 2018 · 5.4K citations · Full text

, , +12

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

Journal of Hepatology · 2016 · 4.8K citations

, , +9